Cognition Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.79
- Today's High:
- $1.96
- Open Price:
- $1.79
- 52W Low:
- $1.07
- 52W High:
- $3.83
- Prev. Close:
- $1.83
- Volume:
- 69795
Company Statistics
- Market Cap.:
- $53.55 million
- Book Value:
- 1.64
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -86%
- Return on Equity TTM:
- -126.08%
Company Profile
Cognition Therapeutics Inc had its IPO on 2021-10-08 under the ticker symbol CGTX.
The company operates in the Healthcare sector and Biotechnology industry. Cognition Therapeutics Inc has a staff strength of 0 employees.
Stock update
Shares of Cognition Therapeutics Inc opened at $1.79 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $1.79 - $1.96, and closed at $1.94.
This is a +6.01% increase from the previous day's closing price.
A total volume of 69,795 shares were traded at the close of the day’s session.
In the last one week, shares of Cognition Therapeutics Inc have increased by +3.74%.
Cognition Therapeutics Inc's Key Ratios
Cognition Therapeutics Inc has a market cap of $53.55 million, indicating a price to book ratio of 1.9673 and a price to sales ratio of 0.
In the last 12-months Cognition Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-45976000. The EBITDA ratio measures Cognition Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cognition Therapeutics Inc’s operating margin was 0% while its return on assets stood at -86% with a return of equity of -126.08%.
In Q4, Cognition Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cognition Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cognition Therapeutics Inc’s profitability.
Cognition Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.3479. Its price to sales ratio in the trailing 12-months stood at 0.
Cognition Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $50.43 million
- Total Liabilities
- $7.80 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $148000
- Dividend Payout Ratio
- 0%
Cognition Therapeutics Inc ended 2023 with $50.43 million in total assets and $0 in total liabilities. Its intangible assets were valued at $50.43 million while shareholder equity stood at $40.25 million.
Cognition Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $7.80 million in other current liabilities, 29000.00 in common stock, $-115401000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $41.56 million and cash and short-term investments were $41.56 million. The company’s total short-term debt was $149,000 while long-term debt stood at $0.
Cognition Therapeutics Inc’s total current assets stands at $47.65 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $3.22 million and inventory worth $0.
In 2023, Cognition Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $148000.
Comparatively, Cognition Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.94
- 52-Week High
- $3.83
- 52-Week Low
- $1.07
- Analyst Target Price
- $10.25
Cognition Therapeutics Inc stock is currently trading at $1.94 per share. It touched a 52-week high of $3.83 and a 52-week low of $3.83. Analysts tracking the stock have a 12-month average target price of $10.25.
Its 50-day moving average was $1.85 and 200-day moving average was $1.99 The short ratio stood at 0.84 indicating a short percent outstanding of 0%.
Around 918.9% of the company’s stock are held by insiders while 5234.8% are held by institutions.
Frequently Asked Questions About Cognition Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer’s disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson’s disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.